Field study to investigate the effectiveness and safety of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio® Plus) against natural flea and tick infestations on dogs presented as veterinary patients in Europe

Table 5 Effectiveness of three consecutive monthly doses of Credelio Plus^® and afoxolaner + milbemycin oxime based on investigator counts of natural live tick infestations for all tick species on client owned dogs in European field study

Study day	Treatment group	n	Live tick counts		% Effectiveness
Study day	Treatment group	n	Range	Arithmetic mean	% Effectiveness
0	Credelio Plus^®	147	3–14	4.6	–
	Afoxolaner + Milbemycin oxime	74	3–18	4.2	–
7 ± 2	Credelio Plus^®	145	0–5	0.08	98.2
	Afoxolaner + Milbemycin oxime	71	0–1	0.03	99.3
14 ± 2	Credelio Plus^®	147	0–1	0.01	99.8
	Afoxolaner + Milbemycin oxime	74	0–1	0.01	99.8
21 ± 2	Credelio Plus^®	144	0–1	0.01	99.8
	Afoxolaner + Milbemycin oxime	73	0–1	0.01	99.8
28 ± 2	Credelio Plus^®	147	0–2	0.03	99.3
	Afoxolaner + Milbemycin oxime	73	0–1	0.01	99.8
42 ± 2	Credelio Plus^®	145	0–0	0	100
	Afoxolaner + Milbemycin oxime	72	0–0	0	100
56 ± 2	Credelio Plus^®	143	0–0	0	100
	Afoxolaner + Milbemycin oxime	72	0–0	0	100
70 ± 2	Credelio Plus^®	135	0–0	0	100
	Afoxolaner + Milbemycin oxime	72	0–0	0	100
84 ± 2	Credelio Plus^®	127	0–0	0	100
	Afoxolaner + Milbemycin oxime	65	0–4	0.06	98.6

ISSN: 1756-3305